Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience

被引：13

作者：

Martinez-Poles, Javier ^{[1
]}

Nedkova-Hristova, Velina ^{[1
]}

Bernardo Escribano-Paredes, Jose ^{[1
]}

Garcia-Madrona, Sebastian ^{[1
]}

Natera-Villalba, Elena ^{[1
]}

Estevez-Fraga, Carlos ^{[1
,2
]}

Lopez-Sendon Moreno, Jose Luis ^{[1
]}

Aviles-Olmos, Iciar ^{[1
]}

Sanchez Diaz, Gema ^{[1
]}

Martinez Castrillo, Juan Carlos ^{[1
]}

Alonso-Canovas, Araceli ^{[1
]}

机构：

[1] Hosp Univ Ramon y Cajal, Dept Neurol, Madrid 28034, Spain

[2] UCL Inst Neurol, Dept Neurodegenerat Dis, London WC1N 3RX, England

来源：

TOXINS | 2018年 / 10卷 / 06期

关键词：

sialorrhea; neurological disorders; Parkinson's disease; botulinum toxin type A; incobotulinumtoxin A; TOXIN TYPE-A; RANDOMIZED CONTROLLED-TRIAL; PARKINSONS-DISEASE; DOUBLE-BLIND; COMPLEXING PROTEINS; BOTULINUM TOXINS; EFFICACY; SAFETY; METAANALYSIS; INJECTION;

D O I：

10.3390/toxins10060217

中图分类号：

TS2 [食品工业];

学科分类号：

0832 ;

摘要：

Botulinum toxin type A is one of the most useful treatments of sialorrhea in neurological disorders. Evidence for the use of incobotulinumtoxin A (inco-A) in the treatment of sialorrhea is limited. Thirty-six patients with sialorrhea were treated with infiltrations of inco-A into both parotid glands. The severity of sialorrhea was evaluated by the Drooling Severity Scale (DSS), and the Drooling Frequency Scale (DFS). Patients' perceptions of clinical benefit were recorded via the Patient Global Impression of Improvement (PGI-I) scale. Following treatment, there was a significant difference in both the DFS and the DSS (p < 0.001). Clinical benefits on the basis of the PGI-I were present in up to 90% of patients.

引用

页数：8

共 50 条

[1] Efficacy of Incobotulinumtoxin/A Treatment for Children/Adolescents with Sialorrhea associated with Neurological Disorders
Berweck, S.
Kim, H.
Banach, M.
Hanschmann, A.
Althaus, M.
Bonikowski, M.
[J]. MOVEMENT DISORDERS, 2021, 36 : S126 - S126
[2] Association between neurological outcome and poststroke comorbid mood and anxiety disorders: A real-life experience
Rabat, Yolaine
Houeze, Richard
Sagnier, Sharmila
Olindo, Stephane
Poli, Mathilde
Debruxelles, Sabrina
Renou, Pauline
Rouanet, Francois
Berthoz, Sylvie
Sibon, Igor
[J]. BRAIN AND BEHAVIOR, 2021, 11 (06):
[3] INCOBOTULINUMTOXINA TO TREAT SIALORRHEA IN PARKINSON'S DISEASE: A REAL-LIFE STUDY
Bergmans, B.
Schotte, V.
Sys, N.
Van Massenhove, E.
Van Zandijcke, M.
[J]. PARKINSONISM & RELATED DISORDERS, 2020, 79 : E69 - E70
[4] Encapsulating real-life experience
Kelly, D
Davey, B
[J]. Information and Communication Technologies and Real-Life Learning: NEW EDUCATION FOR THE KNOWLEDGE SOCIETY, 2005, 182 : 85 - 94
[5] IncobotulinumtoxinA to treat sialorrhea in Parkinson's disease: A real-life study
Bergmans, B.
Schotte, V.
Sys, N.
Van Massenhove, E.
Van Zandijcke, M.
[J]. MOVEMENT DISORDERS, 2020, 35 : S389 - S389
[6] IncobotulinumtoxinA to treat sialorrhea in Parkinson's disease: a real-life study
Bergmans, B.
Winter, N.
Schotte, V.
Sys, N.
Van Massenhove, E.
Couckuyt, H.
Van Zandijcke, M.
[J]. MOVEMENT DISORDERS, 2022, 37 : S319 - S320
[7] Lenvatinib Real-Life Experience
Markman, Maurie
[J]. ONCOLOGY, 2019, 97 (04) : 189 - 190
[8] Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disorders
Fragoso, Yara Dadalti
Adoni, Tarso
Alves-Leon, Soniza Vieira
Apostolos-Pereira, Samira Luisa
Barreira, Amilton Antunes
Bidin Brooks, Joseph Bruno
Claudino, Rinaldo
Correa, Eber Castro
Brito Ferreira, Maria Lucia
Finkelsztejn, Alessandro
Finkelsztejn, Juliana
da Gama, Paulo Diniz
Magno Goncalves, Marcus Vinicius
Guerreiro, Carlos Tostes
da Cunha Matta, Andre Palma
Marques, Vanessa Daccach
Morales, Rogerio Rizo
Koncke Parolin, Monica Fiuza
Ribeiro, Marlise de Castro
Gonsalves Jube Ribeiro, Taysa Alexandrino
Ruocco, Heloisa Helena
Sato, Henry
Scherpenhuijzen, Simone
Siquineli, Fabio
de Carvalho Sousa, Nise Alessandra
Varela, Daniel Lima
Tauil, Carlos Bernardo
Winckler, Thereza Cristina
[J]. NEUROREHABILITATION, 2016, 39 (02) : 301 - 304
[9] SAFETY OF INCOBOTULINUMTOXIN/A IN THE TREATMENT OF 6-TO 17-YEAR-OLD CHILDREN AND ADOLESCENTS WITH CHRONIC SIALORRHEA ASSOCIATED WITH NEUROLOGICAL DISORDERS AND/OR INTELLECTUAL DISABILITY
Berweck, Steffen
Bonikowski, Marcin
Kim, Heakyung
Hanschmann, Angelika
Althaus, Michael
Banach, Marta
[J]. TOXICON, 2021, 190 : S8 - S8
[10] EFFICACY AND SAFETY OF INCOBOTULINUMTOXIN/A IN THE TREATMENT OF 2-TO 5-YEAR-OLD CHILDREN WITH CHRONIC SIALORRHEA ASSOCIATED WITH NEUROLOGICAL DISORDERS AND/OR INTELLECTUAL DISABILITY
Berweck, Steffen
Bonikowski, Marcin
Banach, Marta
Hanschmann, Angelika
Althaus, Michael
Kim, Heakyung
[J]. TOXICON, 2021, 190 : S8 - S9

← 1 2 3 4 5 →